4Sean R Tunis,Daniel B Stryer ,Carolyn M Clancy. Practical clinical trials:Increasing the value of clinical research for decision making in clinical and health policy[J]. JAMA,2003,290(12):1624-1634
6Maynard A. Economic evaluation techniques in healthcare. Reinventing the wheel, Pharmacoeconomics 1997,11:115-118.
7Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of healthcare programes. Oxford: Oxford University Press. 1987.3.
8Johnson JA, Friesen E. Reassessing the relevance of pharmacoeconomic analyses in formulary decisions. Pharmacoeconomics, 1998,13:479-485.
9Laura A. Review of health economic guidelines in the form of regulations, principles, policies and positions. Drug information Journal, 1996,(30):1003-1006.
10Glennie JL, Torrance GW, Baladi JF. The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Phharmacoeconomics, 1999,15:459-468.
2Adams CP,Brantner VV. Estimating the cost of new drug development:is it really $802 million[J]. Health Aff,2006,25(2):420-428.
3DiMasi JA. The value of improving the productivity of the drug development process:faster times and better decisions[J]. Pharmacoeconomies, 2002,20 ( Suppl3 ) : S 1 10.
